Oric Pharmaceuticals offers extraordinary asymmetry with analyst price targets implying 141% upside, but the company is pre-revenue, cash-burning, below the $1 billion market cap investability threshold, and carries 21% short interest, making it a high-risk speculative situation outside the normal investable universe.
Thesis pillars
- Analyst Upside 141pct↓Deteriorating
- High Short Interest 21pct↓Deteriorating
- Cash Burn Quality Floor Breach→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 23, 2026· older than 90 days
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.34: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance mechanisms in cancer, advancing two licensed product candidates: rinzimetostat (licensed from Mirati Therapeutics) for metastatic castration-resistant prostate cancer, and... Read more
Sell if holding. Engine safety override at $9.34: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: speculative.
About Oric Pharmaceuticals, Inc.
About Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals has no approved products and no product revenue, funding a two-asset clinical pipeline with $392.3 million in cash, cash equivalents, and investments as of December 31, 2025 that management expects to last into the second half of 2028. The company's lead candidate, rinzimetostat, licensed from Mirati Therapeutics, is advancing toward a first global Phase 3 registrational trial in metastatic castration-resistant prostate cancer planned for the first half of 2026, alongside enozertinib, licensed from Voronoi Inc., in Phase 1b testing for EGFR exon 20-mutant non-small cell lung cancer.
Since ORIC has no marketed products, it generates no revenue and instead funds development through public and private securities offerings; both lead assets were in-licensed rather than internally discovered, with Johnson & Johnson and Bayer providing clinical trial collaboration and supply agreements to test rinzimetostat alongside their respective androgen-receptor inhibitors Erleada and Nubeqa, and Johnson & Johnson also collaborating on enozertinib combinations with amivantamab. In August 2025, the company narrowed its pipeline to focus exclusively on rinzimetostat and enozertinib, eliminating its discovery research group to preserve capital. ORIC reported a $129.5 million net loss for 2025 against an accumulated deficit of $692.2 million, reflecting the capital intensity typical of clinical-stage biopharmaceutical development with no offsetting product sales.
Show full overview
ORIC's business is substantially dependent on the success of rinzimetostat and enozertinib, according to its own risk factor disclosures, since it has no other late-stage assets to fall back on after its August 2025 decision to eliminate discovery-stage research. Both candidates also carry dependency risk beyond ORIC's control: rinzimetostat rights originate from a Mirati Therapeutics license and enozertinib from a Voronoi Inc. license, so any dispute over those license agreements could affect development or commercialization rights, particularly since ORIC's rights to enozertinib exclude Greater China.
See also: Healthcare · Biotechnology
From Oric Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Oric Pharmaceuticals, Inc.
Latest news
- NEWS ORIC Pharmaceuticals Announces Participation in Upcoming November 2026 Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Analysts Maintain Ratings and Price Targets for ORIC Pharmaceuticals — fiscal.ai Oct 29, 2026 neutral
- NEWS H.C. Wainwright Maintains Buy Rating and $27 Price Target for ORIC Pharmaceuticals — fiscal.ai Oct 28, 2026 positive
- NEWS BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target — benzinga Oct 28, 2026 neutral
- NEWS Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 — benzinga Oct 27, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-05T11:54:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinerinzimetostat and enozertinib10-K Item 1A: 'We are substantially dependent on the success of our product candidates, rinzimetostat and enozertinib.'
Material Events(8-K, last 90d)
- 2026-06-22Item 5.02LOWORIC amended and restated its 2020 Equity Incentive Plan effective June 18, 2026 following stockholder approval at the Annual Meeting, removing the annual share cap on the evergreen provision (while lowering the annual increase from 5% to 4%) and eliminating repricing/award-exchange authority. No officer departure or appointment was involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.34: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.69. Score 5.3/10, moderate confidence.
Analyst target: $18.89 (+102.3% upside). Prior stop was $8.69. Stop-loss: $8.69.
Concentration risk — Pipeline: rinzimetostat and enozertinib; Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.1), Material insider selling (59 sells, 0.76% of cap).
Oric Pharmaceuticals, Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts rate ORIC, with a consensus score of 4.4/5. 14 analysts publish price targets averaging $22.
What does Oric Pharmaceuticals, Inc. do?ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance mechanisms in...
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance mechanisms in cancer, advancing two licensed product candidates: rinzimetostat (licensed from Mirati Therapeutics) for metastatic castration-resistant prostate cancer, and enozertinib (licensed from Voronoi Inc.) for EGFR exon 20-mutant lung cancer. The company has no approved products or product revenue, reported a $129.5 million net loss for 2025, and held $392.3 million in cash as of December 31, 2025.